Ergo Science Corporation, located in Charlestown, Massachusetts, has initiated a human clinical trial for FDA approval of its Ergoset tablets. The tablets are intended to reduce insulin requirements for people with type 2 diabetes who are on insulin.
The object of the trial is to lower BGs and daily insulin requirements of people with type 2 whose BGs have not been sufficiently controlled on oral hypoglycemic agents and insulin. This type of patient represents approximately three million of the seven million type 2s who receive treatment for their diabetes.
Efficient use of insulin for these patients is important as excess insulin in the bloodstream has been associated with cardiovascular disease.
The phase III human clinical trial of Ergoset for FDA approval demonstrated “significant and meaningful results in people with type 2 diabetes,” according to a company press release.